Biotech Values

[DewDiligence]

VRAX IPOs 1.35M shares @$5.00:

https://www.globenewswire.com/news-release/2022/07/21/2483264/0/en/Virax-Biolabs-Group-Limited-Announces-Pricing-of-6-75-Million-Initial-Public-Offering.html

Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.

Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

This is one of the smallest biotech IPOs in recent memory ($6.25M gross proceeds).

The share price has already quadrupled (as I’m typing), so the underwriters evidently left money on the table.